心航路医学完成6亿元B轮融资，美团龙珠基金和礼来亚洲基金联合领投

广州日报2025-05-07

近日，心航路医学科技公司（“心航路医学”）宣布完成6亿元人民币的B轮融资。本轮融资由美团龙珠基金和老股东礼来亚洲基金（LAV）联合领投，老股东龙磐投资继续超额加注。继2023年8月完成近两亿元的A轮融资后，心航路医学再次实现市场化超募融资。此次B轮融资将加速心航路医学核心电生理产品的研发和注册临床试验，并进一步巩固了其在全球电生理领域的技术与产品优势。　　据悉，心航路医学成立于2020年，总部位于...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2533364337?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-07 10:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533364337","market":"us","top_or_hot":-1,"title":"心航路医学完成6亿元B轮融资，美团龙珠基金和礼来亚洲基金联合领投","media":"广州日报","content":"<div>\n<p>近日，心航路医学科技公司（“心航路医学”）宣布完成6亿元人民币的B轮融资。本轮融资由美团龙珠基金和老股东礼来亚洲基金（LAV）联合领投，老股东龙磐投资继续超额加注。继2023年8月完成近两亿元的A轮融资后，心航路医学再次实现市场化超募融资。此次B轮融资将加速心航路医学核心电生理产品的研发和注册临床试验，并进一步巩固了其在全球电生理领域的技术与产品优势。　　据悉，心航路医学成立于2020年，总部位于...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202505073397852628.html\">网页链接</a>\n\n</div>\n","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心航路医学完成6亿元B轮融资，美团龙珠基金和礼来亚洲基金联合领投</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心航路医学完成6亿元B轮融资，美团龙珠基金和礼来亚洲基金联合领投\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-07 10:52 北京时间&nbsp;&nbsp;&nbsp;<a href=http://finance.eastmoney.com/a/202505073397852628.html><strong>广州日报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，心航路医学科技公司（“心航路医学”）宣布完成6亿元人民币的B轮融资。本轮融资由美团龙珠基金和老股东礼来亚洲基金（LAV）联合领投，老股东龙磐投资继续超额加注。继2023年8月完成近两亿元的A轮融资后，心航路医学再次实现市场化超募融资。此次B轮融资将加速心航路医学核心电生理产品的研发和注册临床试验，并进一步巩固了其在全球电生理领域的技术与产品优势。　　据悉，心航路医学成立于2020年，总部位于...</p>\n\n<a href=\"http://finance.eastmoney.com/a/202505073397852628.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0672654240.SGD","symbol_name":"FTIF - Franklin US Opportunities A Acc SGD-H1","start_time":0,"source_url":"http://finance.eastmoney.com/a/202505073397852628.html","article_id":"2533364337","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533364337","pubTimestamp":1746586323,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"近日，心航路医学科技公司（“心航路医学”）宣布完成6亿元人民币的B轮融资。本轮融资由美团龙珠基金和老股东礼来亚洲基金（LAV）联合领投，老股东龙磐投资继续超额加注。继2023年8月完成近两亿元的A轮融资后，心航路医学再次实现市场化超募融资。此次B轮融资将加速心航路医学核心电生理产品的研发和注册临床试验，并进一步巩固了其在全球电生理领域的技术与产品优势。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0588545730.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY INCOME \"ADM\" (USD) INC","03690":"美团-W","SG9999001176.USD":"United Global Healthcare Acc USD","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU0348788117.USD":"ALLIANZ EMERGING ASIA EQUITY \"A\" (USD) INC","BK1615":"港股-互联网","BK1575":"同股不同权","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0165289439.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AC\" ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0385154629.USD":"贝莱德营养科学基金A2","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2152927971.USD":"NORDEA 1 ASIAN STARS EQUITY \"BP\" (USD) ACC","LU0823038988.USD":"AMUNDI FUNDS ASIA EQUITY FOCUS  \"A2\" (USD) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU0541501648.USD":"ALLSPRING  EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","LU2471134796.USD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (USD) INC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0348816934.USD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (USD)","LU0823040885.USD":"东方汇理新兴市场焦点股票基金","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0032431581.USD":"PINEBRIDGE GREATER CHINA EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","LU0051755006.USD":"摩根大通中国A (dist)","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","HMTD.SI":"Meituan HK SDR 5to1","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","BK1618":"Manus概念股","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC","MPNGY":"美团ADR","LU0499858602.USD":"NINETY ONE GSF ASIA PACIFIC EQUITY OPPORTUNITIES \"A\" (USD) ACC","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1048596156.SGD":"Blackrock Asian Growth Leaders A2 SGD-H","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC"},"translate_title":"Xinhanglu Medicine completed 600 million yuan in Series B financing, jointly led by Meituan Dragon Ball Fund and Eli Lilly Asia Fund","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HMTD.SI":0.6,"03690":1,"MPNGY":1},"content_text":"近日，心航路医学科技公司（“心航路医学”）宣布完成6亿元人民币的B轮融资。本轮融资由美团龙珠基金和老股东礼来亚洲基金（LAV）联合领投，老股东龙磐投资继续超额加注。继2023年8月完成近两亿元的A轮融资后，心航路医学再次实现市场化超募融资。此次B轮融资将加速心航路医学核心电生理产品的研发和注册临床试验，并进一步巩固了其在全球电生理领域的技术与产品优势。　　据悉，心航路医学成立于2020年，总部位于广州。公司致力于开发下一代房颤治疗产品，并构建集“磁电导航+五维标测+立体PFA消融”于一体的一站式房颤治疗解决方案。据悉，该公司研发了全球唯一的DePolar®心脏“五维”电生理标测系统，该系统可以实现高精度的“一跳全心腔”实时标测，结合超高密度标测导管LibStar®（天秤星标测导管，96个电极）与DipperStar®（北斗星标测导管，176个电极）和独创的动作电位标测技术，能够实时标测房颤，并根据标测结果进行个体化消融，提升持续性房颤的消融成功率。 （文章来源：广州日报）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2533364337","isCrawlerRequest":true}